NLS Pharmaceutics (NLSP) Stock Forecast, Price Target & Predictions
NLSP Stock Forecast
NLS Pharmaceutics stock forecast is as follows: a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
NLSP Analyst Ratings
According to 2 Wall Street analysts, NLS Pharmaceutics's rating consensus is 'Buy'. The analyst rating breakdown for NLSP stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 08, 2022 | Maxim Group | - | Buy | Upgrade |
| Sep 06, 2022 | Laidlaw | - | Buy | Initialise |
NLS Pharmaceutics's last stock rating was published by Maxim Group on Dec 08, 2022. The company Upgrade its NLSP rating from "null" to "Buy".
NLS Pharmaceutics Financial Forecast
NLS Pharmaceutics Revenue Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Avg Forecast | - | - | - | - |
| High Forecast | - | - | - | - |
| Low Forecast | - | - | - | - |
| # Analysts | - | - | - | - |
| Surprise % | - | - | - | - |
NLS Pharmaceutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. NLSP's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
NLS Pharmaceutics EBITDA Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| EBITDA | - | - | - | - |
| Avg Forecast | - | - | - | - |
| High Forecast | - | - | - | - |
| Low Forecast | - | - | - | - |
| Surprise % | - | - | - | - |
undefined analysts predict NLSP's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than NLS Pharmaceutics's previous annual EBITDA (undefined) of $NaN.
NLS Pharmaceutics Net Income Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| Net Income | - | - | - | - |
| Avg Forecast | $49.99M | $43.54M | $51.12M | $67.72M |
| High Forecast | $49.99M | $43.54M | $51.12M | $67.72M |
| Low Forecast | $49.99M | $43.54M | $51.12M | $67.72M |
| Surprise % | - | - | - | - |
NLS Pharmaceutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NLSP's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
NLS Pharmaceutics SG&A Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| SG&A | - | - | - | - |
| Avg Forecast | - | - | - | - |
| High Forecast | - | - | - | - |
| Low Forecast | - | - | - | - |
| Surprise % | - | - | - | - |
NLS Pharmaceutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to NLSP last annual SG&A of $NaN (undefined).
NLS Pharmaceutics EPS Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| EPS | - | - | - | - |
| Avg Forecast | $1.54 | $1.34 | $1.58 | $2.09 |
| High Forecast | $1.54 | $1.34 | $1.58 | $2.09 |
| Low Forecast | $1.54 | $1.34 | $1.58 | $2.09 |
| Surprise % | - | - | - | - |
According to undefined Wall Street analysts, NLS Pharmaceutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NLSP previous annual EPS of $NaN (undefined).
NLS Pharmaceutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| NLSP | NLS Pharmaceutics | $0.14 | $6.00 | 4185.71% | Buy |
| MOLN | Molecular Partners | $5.22 | $29.00 | 455.56% | Buy |
| CTMX | CytomX Therapeutics | $1.23 | $5.77 | 369.11% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.08 | $6.00 | 188.46% | Buy |
| ACHL | Achilles Therapeutics | $0.72 | $2.00 | 177.78% | Buy |
| RZLT | Rezolute | $5.25 | $13.00 | 147.62% | Buy |
| ACRV | Acrivon Therapeutics | $8.91 | $21.50 | 141.30% | Buy |
| ELYM | Eliem Therapeutics | $8.46 | $13.00 | 53.66% | Buy |
| TIL | Instil Bio | $84.52 | $17.67 | -79.09% | Hold |
NLSP Forecast FAQ
Is NLS Pharmaceutics a good buy?
Yes, according to 2 Wall Street analysts, NLS Pharmaceutics (NLSP) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of NLSP's total ratings.
What are NLS Pharmaceutics's analysts' financial forecasts?
NLSP's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $67.72M (high $67.72M, low $67.72M), average SG&A $0 (high $0, low $0), and average EPS is $2.09 (high $2.09, low $2.09).